Analysed ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) News Sources
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
28-04-2026
yahoo.com
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus
28-04-2026
marketbeat.com
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
04-05-2026
yahoo.com
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
07-05-2026
yahoo.com
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
08-05-2026
yahoo.com
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
28-05-2026
yahoo.com
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
04-06-2026
marketbeat.com
What is the current price of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The current price of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is $4.34.
ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) since the previous trading day is $-0.02.
ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) since the previous trading day is -0.4587%.
What is the most recent average sentiment score for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The most recent average sentiment score for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The most recent sentiment for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is .
SEC-8K** Filing Available For ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.